CN106619816A - Pharmaceutical composition for treating optic atrophy - Google Patents
Pharmaceutical composition for treating optic atrophy Download PDFInfo
- Publication number
- CN106619816A CN106619816A CN201611133256.5A CN201611133256A CN106619816A CN 106619816 A CN106619816 A CN 106619816A CN 201611133256 A CN201611133256 A CN 201611133256A CN 106619816 A CN106619816 A CN 106619816A
- Authority
- CN
- China
- Prior art keywords
- weight
- ethanol
- extract
- pharmaceutical composition
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a pharmaceutical composition for treating optic atrophy and a preparation method thereof. The pharmaceutical composition is prepared from bark of Japanese spicebush, Szechwan-Yunnan sanicle herb, asarinin, genistin, and hederagenin according to a ratio; the pharmaceutical composition may be made into various forms of drug according to conventional pharmaceutical processes to treat optic atrophy significantly.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, more particularly to a kind of pharmaceutical composition for treating optic atrophy and its preparation
Method.
Background technology
Optic atrophy is in the presence of some diseases or paathogenic factor to send out retinal ganglial cells and its aixs cylinder
Sick change, finally makes optic nerve all attenuate.In terms of ophtalmic treatments, Eye injuries cause optic atrophy to belong to one of difficult disease, are
Clinically relatively conventional illness, there is no at present specific treatment in treatment.Especially the patient long to post burn be more
It is that curative effect is little.
Among the various causes of disease of blinding, eye traumas is in occupation of main positions.When eye socket occurs bone in the presence of external force
Folding or wounding, in the presence of the blunt forces such as boxing injury oppression eyeball so as to when Posterior pole retina train of thought oedema is gushed out, can cause
Optic nerve is oppressed, and this exactly causes the one of the main reasons of optic atrophy.Optic nerve is direct in the presence of external force
It is injured；Optic nerve is destroyed rapidly and is caused its atrophy under the influence of some pathologies.In the early stage fashion can absorb oedema
And bleeding, afflicted area is further reduced, make function be restored.But if necrosing, the permanent of optic nerve is will result in
Atrophy, while can also lose correlation function.Observing eye bottom is pale for optic disk at the beginning, and blood vessel attenuates and even disappear, and is spaced several weeks
Can just find that atrophy occurs in nipple afterwards, border is clearly demarcated, and blood vessel is normal.And during the eye traumas of doctor trained in Western medicine causes optic atrophy to refer to
Its Chinese pathology mechanism and treatment method are sought in the glaucoma of doctor or collision injury eyeball.Motherland's medical science thinks, passivity external force collision eye,
Eyeball is damaged, and then causes body deficiency of qi and blood, makes blood extravasation of blood, overflows outside arteries and veins, or qi and blood stagnation mesh system train of thought, causes born of the same parents
The positions such as eyelid, white of the eye, black eyeball or eyeball pearl are injured, occur the symptoms such as visual impairment, diplopia, mesh pain, stasis of blood in the eyelid the eyelid of purple color swelling, bleeding or
Sign, if fail treatment in time or occur controlling by mistake, train of thought is obstructed and is increased, it is seen that mesh key is inaccessible, causes anopia.For causing
The reason for optic atrophy, invigorating spleen for diuresis, promoting blood circulation and removing blood stasis is focused on during tcm syndrome differentiation and treatment, such as occur oedema product for qi stagnation blood stasis
Liquid, can select activating blood and promoting diuresis method.Aqueous in tissue were blood component originally, and under wound effect, imbalance occurs in zang-fu organs qi movement,
Cause blood obstacle, defeated cloth and the excretion of aqueous is have impact on to a great extent, stop after accumulation and form oedema.In view of
This, will treat this disease, and needs are conceived to promoting blood circulation while also to take into account Li Shui.
Japanese spicebush bark：For Lauraceae Lindera plant Cortex Linderae Obtusilobae Lindera obtusiloba Bl.
The bark of [L.cercidifolia Hemsl.].The four seasons can adopt, and dry.【Nature and flavor】It is pungent；Temperature.【Return through】Stomach；Liver Channel.【Function
Cure mainly】Middle benefit gas promoting the circulation of qi；Promoting blood circulation to remove blood stasis.Main trusted subordinate's pain；Traumatic injury；Blood stasis and swelling pain；Sore.【Chemical analysis】Trunk contains paddy
Sterol, stigmasterol and campesterol (Campesterol).Branches and leaves 0.4-0.6% containing aromatic oil, predominantly l-borneol (Linde-
rol).Leaf has the linear paraffin containing carbon number from 16-33.Contain capric acid (Capric acid), laurate (Lauric in seed oil
Acid), nutmeg acid (14 (alkane) acid, Myristic acid), cis-dodecenoic acid (Linderic acid, Dodecen-4-
Oic acid), decenoic acid (Decenoic acid), obtusilic acid (Decen-4-oic acid, Obtusilic
Acid), tetracecen-4-oic acid (Tetradecen-4-oic acid, Tsudzuic acid), oleic acid (Oleic acid) and Asia
Oleic acid (Linoleic acid) etc..【Proterties】Bark is in thin drum, long 16-25cm, wide 2cm, thick 1.5-2mm.Outer surface ash
Brown, coarse, the irregular thin longitudinal grin of tool and spot block texture, the little hole skin of bossed similar round, cork come off or scrape off after compared with
Smooth, brown color is to rufous；Inner surface rufous, flat, it is seen that thin longitudinal grin, that what is drawn shows slightly oil trace.Matter is firmly crisp, plane of rupture compared with
It is flat.Outer layer brown color, internal layer rufous and slightly oil.Gas micro-perfume, lightly seasoned, micro-pungent.Record in dictionary of medicinal plant.
Szechwan-Yunnan sanicle herb：This product is samphire river Yunnan sanicle Sanicula astrantifolia Wolff ex
Kresch. herb.The 6-9 months harvest, and dry.【Nature and flavor】Pungent, slight bitter, temperature.【Return through】Return liver warp.【Indication】Wines used as antirheumatic；
Degrading the channel.Main arthralgia due to wind-dampness；Muscle arteries and veins contraction；Traumatic injury.【Former phytomorph】Perennial herb, high 30-70cm.Complete stool without
Hair.Root tubbiness, there is most elongated supporting roots.Stem is upright, and top is stood, top 2-4 dichotomies.The long 5-20cm of basal leaf petiole, base
There is wide film quality sheath in portion.Blade nearly keratin, heart shaped triangle forms round kidney shape, long 2.5-8cm, wide 2.5-9cm, and palmate three is molten to be split, in
Between sliver width obovate, side sliver whip shape ovum shape lanceolar has 1-2 to incise deeply again sometimes, and there is thick crenature at edge, and increment has
Mucro, palmate vein 3-5.Universal umbel basidixed；Phyllary is several, linear；Umbrella spoke minority；Involucel piece 7-10, it is linear；It is little
Umbel has about 10, flower；Calyx tooth wire lanceolar；Petal obovate, white or pink；Style outwards launches.Diachenium
Inverted cone-shaped, is about 2mm, below prickle it is short, top prickle in hook-shaped, golden yellow or aubergine；Mitogenetic fruit cross section is rounded,
The endosperm outside of belly is straight, and oil pipe is little, not substantially.Flower, the fruiting period 7-10 month.Record in dictionary of medicinal plant.
Genistin（Genistin）：CAS 529-59-9, molecular formula C21H20O10, molecular weight 432.38.【Pharmacology is made
With】There is estrogen active, the appetite and body weight of male and ovariectomized hamster can be increased after clothes.【Purposes】Sex hormone.【Composition
Source】Legume dyewood (broom top) Genista tionctoria Linn., soybean Glycine max (L.)
Merr. seed, the real fruits of Chinese scholartree Sophora japonica L., yellow plumage French beans Lupinus luteus L. roots, Nepal chrysanthemum
Wooden Piptanthus nepalensis (Hook.) D. Don stems.
Hederagenin（Hederagenin）：CAS 465-99-6, molecular formula C30H48O4, molecular weight 472.70.【It is raw
Thing activity】It is antimycotic.【Ingredient origin】Chinese bulbul Pulsatilla chinensis, teasel Dipsacus asperoides,
Caulis aristologhiae manshuriensis Aristolochia manshuriensis, patrinia scabiosaefolia Fiscs Patrinia scabiosaefolia, honeysuckle
Lonicera japonica, deer grass Rhaponticum carthamoides, akebi Akebia quinata, the root of Chinese clematis
Clematis chinensis。
Asarinin（Asarinin ）：CAS 133-05-1, molecular formula C20H18O6, molecular weight 354.35.【Pharmacology is made
With】Sensitization is have to Dalmatian chrysanthemum.【Ingredient origin】Arnold jacquard weave green pepper Zanthaxylum arnottianum, get Ka Rui spend
Green pepper Zanthoxylum decatyi, pepper Chinese prickly ash Zanthoxylum piperitum, royal paulownia Paulownia
Tomentosa, root of Chinese wild ginger A.sarum .sieboldii.
3 bulk drug chemical constitutions：
Hederagenin（Hederagenin）
Genistin（Genistin）Asarinin（Asarinin ）.
The content of the invention
The purpose of the present invention is to overcome the shortcomings of background technology, there is provided a kind of drug regimen of effectively treatment optic atrophy
Thing and preparation method thereof.
The present invention adopts the following technical scheme that realization：
The composition and weight portion for making the bulk drug of the pharmaceutical composition of the treatment optic atrophy be：
Japanese spicebush bark 481-487 weight portion szechwan-Yunnan sanicle herb 264-268 weight portion asarinin 42-48 weight portion genistins
34-36 weight portion hederagenin 8-10 weight portions.
The pharmaceutical composition for the treatment of optic atrophy is preferably used in, is made up of the bulk drug of following weight portion：
Japanese spicebush bark 484 weight portion szechwan-Yunnan sanicle herb, 266 weight portion asarinin, 45 weight portion genistin, 35 weight portions are normal
The weight portion of spring rattan sapogenin 9.
A kind of pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition can adopt the normal of galenic pharmacy
Rule method prepares piece agent or capsule or dripping pill.
A kind of pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition is constituted with chemical drugs or Chinese medicine
Treatment optic atrophy medicine.
A kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug is japanese spicebush bark 481-487 weight portion szechwan-Yunnan sanicle herb 264-268 weight portion root of Chinese wild ginger fat
Plain 42-48 weight portions genistin 34-36 weight portion hederagenin 8-10 weight portions；
Preparation method：
（1）Japanese spicebush bark, szechwan-Yunnan sanicle herb, asarinin, genistin, hederagenin are taken by bulk drug proportioning, is mixed, used
Used as solvent, 32 DEG C of temperature extractions take the ethanol of weight percent concentration 42%, and extraction time is 9 times, and each extraction time is 38 little
When, each solvent load is 37 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, dense
Relative density 1.06 is reduced to, is filtered, liquid is first washed with water by HPD750 large pore resin absorption columns, then uses percentage by weight
The ethanol solution of concentration 14% elutes HPD750 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 14%, reclaims
Ethanol, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 74% as solvent, heating and refluxing extraction 14 times, carries every time
The time is taken for 0.3 hour, each solvent load is 19 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.13 is concentrated into, is filtered, liquid is first washed with water by HP20 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 62% elutes HP20 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 62%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Preferred a kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that make as follows
It is standby：
The composition and weight portion of bulk drug be：The weight of 484 weight portion szechwan-Yunnan sanicle herb of japanese spicebush bark, 266 weight portion asarinin 45
The weight portion of 35 weight portion hederagenin of part genistin 9；
Preparation method：
（1）Japanese spicebush bark, szechwan-Yunnan sanicle herb, asarinin, genistin, hederagenin are taken by bulk drug proportioning, is mixed, used
Used as solvent, 32 DEG C of temperature extractions take the ethanol of weight percent concentration 42%, and extraction time is 9 times, and each extraction time is 38 little
When, each solvent load is 37 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, dense
Relative density 1.06 is reduced to, is filtered, liquid is first washed with water by HPD750 large pore resin absorption columns, then uses percentage by weight
The ethanol solution of concentration 14% elutes HPD750 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 14%, reclaims
Ethanol, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 74% as solvent, heating and refluxing extraction 14 times, carries every time
The time is taken for 0.3 hour, each solvent load is 19 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.13 is concentrated into, is filtered, liquid is first washed with water by HP20 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 62% elutes HP20 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 62%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
A kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition can be adopted
The conventional method of galenic pharmacy prepares piece agent or capsule or dripping pill.
A kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that pharmaceutical composition and chemical drugs
Or Chinese medicine composition treatment optic atrophy medicine.
Medicine composite for curing optic atrophy is evident in efficacy.
Specific embodiment
Embodiment 1：Pharmaceutical composition for the treatment of optic atrophy and preparation method thereof
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：Japanese spicebush bark 484g szechwan-Yunnan sanicle herbs
266g asarinin 45g genistin 35g hederagenin 9g；
Preparation method：
（1）Japanese spicebush bark, szechwan-Yunnan sanicle herb, asarinin, genistin, hederagenin are taken by bulk drug proportioning, is mixed, used
Used as solvent, 32 DEG C of temperature extractions take the ethanol of weight percent concentration 42%, and extraction time is 9 times, and each extraction time is 38 little
When, each solvent load is 37 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, dense
Relative density 1.06 is reduced to, is filtered, liquid is first washed with water by HPD750 large pore resin absorption columns, then uses percentage by weight
The ethanol solution of concentration 14% elutes HPD750 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 14%, reclaims
Ethanol, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 74% as solvent, heating and refluxing extraction 14 times, carries every time
The time is taken for 0.3 hour, each solvent load is 19 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.13 is concentrated into, is filtered, liquid is first washed with water by HP20 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 62% elutes HP20 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 62%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 2：Pharmaceutical composition for the treatment of optic atrophy and preparation method thereof
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：Japanese spicebush bark 481g szechwan-Yunnan sanicle herbs
268g asarinin 42g genistin 36g hederagenin 8g；
Preparation method：
（1）Japanese spicebush bark, szechwan-Yunnan sanicle herb, asarinin, genistin, hederagenin are taken by bulk drug proportioning, is mixed, used
Used as solvent, 32 DEG C of temperature extractions take the ethanol of weight percent concentration 42%, and extraction time is 9 times, and each extraction time is 38 little
When, each solvent load is 37 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, dense
Relative density 1.06 is reduced to, is filtered, liquid is first washed with water by HPD750 large pore resin absorption columns, then uses percentage by weight
The ethanol solution of concentration 14% elutes HPD750 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 14%, reclaims
Ethanol, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 74% as solvent, heating and refluxing extraction 14 times, carries every time
The time is taken for 0.3 hour, each solvent load is 19 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.13 is concentrated into, is filtered, liquid is first washed with water by HP20 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 62% elutes HP20 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 62%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 3：Pharmaceutical composition for the treatment of optic atrophy and preparation method thereof
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：Japanese spicebush bark 487g szechwan-Yunnan sanicle herbs
264g asarinin 48g genistin 34g hederagenin 10g；
Preparation method：
（1）Japanese spicebush bark, szechwan-Yunnan sanicle herb, asarinin, genistin, hederagenin are taken by bulk drug proportioning, is mixed, used
Used as solvent, 32 DEG C of temperature extractions take the ethanol of weight percent concentration 42%, and extraction time is 9 times, and each extraction time is 38 little
When, each solvent load is 37 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, dense
Relative density 1.06 is reduced to, is filtered, liquid is first washed with water by HPD750 large pore resin absorption columns, then uses percentage by weight
The ethanol solution of concentration 14% elutes HPD750 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 14%, reclaims
Ethanol, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 74% as solvent, heating and refluxing extraction 14 times, carries every time
The time is taken for 0.3 hour, each solvent load is 19 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.13 is concentrated into, is filtered, liquid is first washed with water by HP20 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 62% elutes HP20 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 62%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
Embodiment 4：The preparation of tablet
The pharmaceutical composition 425g of Example 1, adds starch 155g, mixes, and granulation is dried, plus microcrystalline cellulose 154g, stearic
Sour magnesium 10g, mixes, and is pressed into 3000, obtains final product medicinal composition tablets.
Embodiment 5：The preparation of capsule
The pharmaceutical composition 330g of Example 2, adds starch 440g, mixes, and granulation is dried, whole grain, adds appropriate stearic acid
Magnesium, mixes, and encapsulated 2100, obtains final product medicament composition capsule.
Embodiment 6：The preparation of dripping pill
Weigh (80 DEG C) heating of Macrogol 6000 216g water-baths and boil molten, add the g of 3 pharmaceutical composition of embodiment 8, fully stir
Mix uniform, with atoleine as cooling agent, put glass tube（4*80cm）In, chilling temperature is -4 DEG C, and drip internal-and external diameter is 7.0/
2.0 (mm/mm), drip is 2.5cm away from liquid level, and drop speed, as optimum condition, with cotton the cold of dripping pill surface is blotted with per point 54 drops
Solidifying agent, obtains final product medicament composition dropping pills.
Embodiment 7：The pharmaceutical composition for the treatment of optic atrophy
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 130 weight portion genistin of asarinin, 2 weight portion hederagenin 40.
Embodiment 8：The pharmaceutical composition for the treatment of optic atrophy
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 20 weight portion genistin of asarinin, 120 weight portion hederagenin 2.
Embodiment 9：The pharmaceutical composition for the treatment of optic atrophy
Treatment optic atrophy pharmaceutical composition bulk drug composition and weight portion be：
The weight portion of 30 weight portion genistin of asarinin, 120 weight portion hederagenin 3.
Experimental example 1：The experimental study for the treatment of optic atrophy
1. clinical data
The Eye injuries that this city hospital accepts for medical treatment in May, 2011～2012 year April cause optic atrophy 28, are randomly divided into and control
Treatment group and control group, 25 eyes for the treatment of group 14,25 eyes of control group 14.Wherein treatment group is male 7, female 7, right eye 10
Example, left eye 15,16～55 years old age, the course of disease 2 months～15 years.Traumatogenic reason：Boxing injury, traffic accident is stabbed, and is wounded,
Damage；Control group man 7, female 7, right eye 10, left eye 15,16～55 years old age, the course of disease 2 months～15 years.Cause injury original
Cause：Boxing injury, traffic accident is stabbed, and is wounded, and is damaged.Two groups of patients compare no difference of science of statistics in physical data（P ＞
0.05）, with comparativity.
2. treatment method
Control group adopts western medicine, the Ai Luming parenteral solution retrobulbar injections of 130mg, interval 1d can be adopted to inject once, 1 treatment
Journey is 25 times, is treated again after 10d, and the main points of retrobulbar injection were ensured that the week of drug injection to optic nerve accurately
Enclose, should also add with inosine, atriphos and vitamins etc. after injection.Treatment group is on the basis for the treatment of of control group scheme
Upper addition treatment by Chinese herbs, with invigorating spleen for diuresis, promoting blood circulation and removing blood stasis as treatment method, using pharmaceutical composition（The drug regimen of embodiment 1
Thing）Orally, each 1.1g, 3 times a day.
3. criterion of therapeutical effect
It is effective：By light sensation, no light perception, index, manual and 0.02 each behavior sequence, eyesight improves three rows and the visual field is more than
20 degree of patient.Effectively：Patient's vision improves three rows, and after being calculated using logarithm eyesight 0.2 is improve, while the visual field
Expand the patient more than 10 degree.It is invalid：The eyesight of patient and the visual field are not improved.
4. statistical method
This group of data are analyzed and are processed using SPSS12.0 statistics softwares, and enumeration data adopts Chi-square Test, metering money
Material is checked using t, and P ＜ 0.05 have statistical significance for difference.
5. treatment results
After 14 patients for the treatment of group are treated using the method for the combination of Chinese tradiational and Western medicine, there are 12 eyes effective, 12 eyes are effective, 1
Eye is invalid, and total effective rate is 96%, and the eyesight of patient improves more than 3 rows, and the enlarging amplitude in the visual field is also more than 20 degree.
Control group has 6 eyes effective, and effectively, 12 eyes are invalid, and total effective rate is 52% for 7 eyes.Two groups of Comparison of therapeutic have conspicuousness poor
It is different, with statistical significance（P ＜ 0.05）.
Claims (8)
1. a kind of pharmaceutical composition for treating optic atrophy, it is characterised in that make the composition of the bulk drug of the pharmaceutical composition
It is with weight portion：
Japanese spicebush bark 481-487 weight portion szechwan-Yunnan sanicle herb 264-268 weight portion asarinin 42-48 weight portion genistins
34-36 weight portion hederagenin 8-10 weight portions.
2. a kind of pharmaceutical composition for treating optic atrophy according to claim 1, it is characterised in that make the medicine group
The composition and weight portion of the bulk drug of compound be：
Japanese spicebush bark 484 weight portion szechwan-Yunnan sanicle herb, 266 weight portion asarinin, 45 weight portion genistin, 35 weight portions are normal
The weight portion of spring rattan sapogenin 9.
3. a kind of pharmaceutical composition for treating optic atrophy according to claim 1, it is characterised in that pharmaceutical composition can
To prepare piece agent or capsule or dripping pill using the conventional method of galenic pharmacy.
4. a kind of pharmaceutical composition for treating optic atrophy according to claim 1, it is characterised in that pharmaceutical composition with
The treatment optic atrophy medicine of chemical drugs or Chinese medicine composition.
5. a kind of preparation method of the pharmaceutical composition for treating optic atrophy, it is characterised in that prepare as follows：
The composition and weight portion of bulk drug be：Japanese spicebush bark 481-487 weight portion szechwan-Yunnan sanicle herb 264-268 weight portion root of Chinese wild ginger fat
Plain 42-48 weight portions genistin 34-36 weight portion hederagenin 8-10 weight portions；
Preparation method：
（1）Japanese spicebush bark, szechwan-Yunnan sanicle herb, asarinin, genistin, hederagenin are taken by bulk drug proportioning, is mixed, used
Used as solvent, 32 DEG C of temperature extractions take the ethanol of weight percent concentration 42%, and extraction time is 9 times, and each extraction time is 38 little
When, each solvent load is 37 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, dense
Relative density 1.06 is reduced to, is filtered, liquid is first washed with water by HPD750 large pore resin absorption columns, then uses percentage by weight
The ethanol solution of concentration 14% elutes HPD750 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 14%, reclaims
Ethanol, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 74% as solvent, heating and refluxing extraction 14 times, carries every time
The time is taken for 0.3 hour, each solvent load is 19 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.13 is concentrated into, is filtered, liquid is first washed with water by HP20 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 62% elutes HP20 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 62%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
6. a kind of preparation method of the pharmaceutical composition for treating optic atrophy according to claim 5, it is characterised in that press
It is prepared by following steps：
The composition and weight portion of bulk drug be：The weight of 484 weight portion szechwan-Yunnan sanicle herb of japanese spicebush bark, 266 weight portion asarinin 45
The weight portion of 35 weight portion hederagenin of part genistin 9；
Preparation method：
（1）Japanese spicebush bark, szechwan-Yunnan sanicle herb, asarinin, genistin, hederagenin are taken by bulk drug proportioning, is mixed, used
Used as solvent, 32 DEG C of temperature extractions take the ethanol of weight percent concentration 42%, and extraction time is 9 times, and each extraction time is 38 little
When, each solvent load is 37 times of bulk drug gross weight, filters, and obtains dregs of a decoction A and extract A, and extract A reclaims ethanol, dense
Relative density 1.06 is reduced to, is filtered, liquid is first washed with water by HPD750 large pore resin absorption columns, then uses percentage by weight
The ethanol solution of concentration 14% elutes HPD750 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 14%, reclaims
Ethanol, concentrate drying obtains final product extract A；
（2）Take step（1）Dregs of a decoction A, with the ethanol of weight percent concentration 74% as solvent, heating and refluxing extraction 14 times, carries every time
The time is taken for 0.3 hour, each solvent load is 19 times of dregs of a decoction A weight, filters, obtain dregs of a decoction B and extract B, extract B is returned
Ethanol is received, relative density 1.13 is concentrated into, is filtered, liquid is first washed with water by HP20 large pore resin absorption columns, then uses weight
The ethanol solution of percent concentration 62% elutes HP20 large pore resin absorption columns, collects the ethanol eluate of weight percent concentration 62%,
Ethanol is reclaimed, concentrate drying obtains final product extract B；
（3）Extract A and extract B are mixed, pharmaceutical composition is obtained final product.
7. a kind of preparation method of the pharmaceutical composition for treating optic atrophy according to claim 5, it is characterised in that medicine
Compositions can adopt the conventional method of galenic pharmacy to prepare piece agent or capsule or dripping pill.
8. a kind of preparation method of the pharmaceutical composition for treating optic atrophy according to claim 5, it is characterised in that medicine
Compositions and chemical drugs or Chinese medicine composition treatment optic atrophy medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611133256.5A CN106619816A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for treating optic atrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611133256.5A CN106619816A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for treating optic atrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106619816A true CN106619816A (en) | 2017-05-10 |
Family
ID=58825316
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611133256.5A Withdrawn CN106619816A (en) | 2016-12-10 | 2016-12-10 | Pharmaceutical composition for treating optic atrophy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106619816A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011293A1 (en) * | 2017-07-13 | 2019-01-17 | 华东理工大学 | Saponin compound targeting pd-1 and application thereof |
-
2016
- 2016-12-10 CN CN201611133256.5A patent/CN106619816A/en not_active Withdrawn
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019011293A1 (en) * | 2017-07-13 | 2019-01-17 | 华东理工大学 | Saponin compound targeting pd-1 and application thereof |
| GB2578390A (en) * | 2017-07-13 | 2020-05-06 | Univ East China Science & Tech | Saponin compound targeting PD-1 and application thereof |
| GB2578390B (en) * | 2017-07-13 | 2022-08-31 | Univ East China Science & Tech | Saponin compound targeting PD-1 and application thereof |
| US11464795B2 (en) | 2017-07-13 | 2022-10-11 | East China University Of Science And Technology | Saponin compound targeting PD-1 and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104225265B (en) | A kind of Traditional Chinese medicine composition for relieving asthenopia | |
| CN101897821B (en) | Granular preparation for promoting blood circulation, dredging collaterals and relieving pain and preparation method as well as detection method thereof | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN105596843A (en) | Medicine composition for treating cerebral thrombosis and preparation method thereof | |
| CN106619816A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN102846871A (en) | Chinese herbal preparation for treating liver-fire ascending type supraorbital neuralgia and preparation method thereof | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN104958566A (en) | Pharmaceutical composition for treating diabetic retinopathy caused by deficiency of both vital energy and yin and preparation method of pharmaceutical composition | |
| CN104906394A (en) | Traditional Chinese medicine for treating liver and kidney yin deficiency and qi and blood deficiency type hypertension | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN104622987B (en) | A kind of pharmaceutical composition for treating chronic hepatitis liver cirrhosis and application | |
| CN1201811C (en) | Chinese medicine composition for treating myopia and preparing method thereof | |
| CN110403988B (en) | A Chinese medicinal ointment with effects of promoting blood circulation and removing blood stasis, and its preparation method | |
| CN106822206A (en) | It is a kind of to treat pharmaceutical composition of neurodermatitis and preparation method thereof | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN105833064A (en) | Eyesight-improving decoction for treating diabetic retinopathy | |
| CN105395710A (en) | Folium artemisiae argyi-containing traditional Chinese medicine preparation for treating fundus hemorrhage and preparing method thereof | |
| CN104162112B (en) | A kind of pharmaceutical composition and preparation method thereof | |
| CN106539934A (en) | A kind of pharmaceutical composition for treating optic atrophy | |
| CN106728142A (en) | A kind of pharmaceutical composition for treating optic atrophy | |
| CN106540090A (en) | Prevent and treat pharmaceutical composition of optic atrophy and preparation method thereof | |
| CN106511642A (en) | Pharmaceutical composition preventing diabetic retinopathy and preparation method for pharmaceutical composition | |
| CN113908235A (en) | Traditional Chinese medicine compound preparation for treating diabetic retinopathy and preparation method and application thereof | |
| CN106619754A (en) | Medicine compound for treating glaucoma | |
| CN106728299A (en) | It is a kind of to treat pharmaceutical composition of protrusion of lumber intervertebral disc and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170510 |
|
| WW01 | Invention patent application withdrawn after publication |